Richard William Scalzo Sells 1,343 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,343 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total value of $15,283.34. Following the sale, the senior vice president now owns 122,330 shares in the company, valued at $1,392,115.40. The trade was a 1.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $12.05 on Friday. Dyne Therapeutics, Inc. has a 1 year low of $11.18 and a 1 year high of $47.45. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -3.38 and a beta of 1.11. The firm’s 50-day moving average is $14.83 and its two-hundred day moving average is $25.63.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on DYN shares. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. BMO Capital Markets assumed coverage on shares of Dyne Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $50.00 price objective for the company. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Friday, February 28th. Finally, Scotiabank assumed coverage on Dyne Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.85.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter worth $34,000. Point72 DIFC Ltd bought a new position in Dyne Therapeutics in the third quarter worth about $36,000. US Bancorp DE lifted its position in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at about $50,000. Finally, KBC Group NV grew its position in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.